Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma? 2006

Omer Cengiz, and Belma Kocer, and Süleyman Sürmeli, and Mary-Jo Santicky, and Atilla Soran
Second Surgery Clinic, Ankara Numune Teaching and Research Hospital, Ankara, Turkey.

BACKGROUND The purpose of this study was to determine if pretreatment serum albumin and cholesterol levels are prognostic factors in patients with colorectal carcinomas. METHODS Ninety-nine patients with colorectal carcinoma were included in this study. Retrospective data analysis included the clinicopathological parameters of age and gender; emergent surgical intervention; stage at presentation; tumor location, size, and differentiation; lymph node metastases; lymphatic, venous and perineural invasion; preoperative serum albumin, cholesterol, hemoglobin, and CEA levels; the presence of preoperative and postoperative metastases; and tumor recurrence. RESULTS Low levels of serum albumin, advanced TNM stage, presence of venous invasion, and high CEA levels were independently correlated with prognosis in multivariate analysis. Advanced stage and low levels of serum cholesterol were found to be a statistically significant parameter for disease free survival. Mean serum albumin levels were found to be decreased in patients with advanced stage, which correlated with increased tumor burden. Although not statistically significant for cholesterol levels, the patients with low serum albumin and low cholesterol levels had shorter overall survival than patients with normal serum albumin and normal cholesterol levels. CONCLUSIONS These results suggest that a preoperative low level of serum albumin can be an indicator for the malignant potential of the tumor and represents an unfavorable prognosis for patients with colorectal carcinoma.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Omer Cengiz, and Belma Kocer, and Süleyman Sürmeli, and Mary-Jo Santicky, and Atilla Soran
February 2016, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,
Omer Cengiz, and Belma Kocer, and Süleyman Sürmeli, and Mary-Jo Santicky, and Atilla Soran
January 2016, OncoTargets and therapy,
Omer Cengiz, and Belma Kocer, and Süleyman Sürmeli, and Mary-Jo Santicky, and Atilla Soran
June 1998, Journal of the Royal College of Surgeons of Edinburgh,
Omer Cengiz, and Belma Kocer, and Süleyman Sürmeli, and Mary-Jo Santicky, and Atilla Soran
January 2016, OncoTargets and therapy,
Omer Cengiz, and Belma Kocer, and Süleyman Sürmeli, and Mary-Jo Santicky, and Atilla Soran
January 2019, Journal of Cancer,
Omer Cengiz, and Belma Kocer, and Süleyman Sürmeli, and Mary-Jo Santicky, and Atilla Soran
February 2019, Anticancer research,
Omer Cengiz, and Belma Kocer, and Süleyman Sürmeli, and Mary-Jo Santicky, and Atilla Soran
January 2018, BioMed research international,
Omer Cengiz, and Belma Kocer, and Süleyman Sürmeli, and Mary-Jo Santicky, and Atilla Soran
February 2015, Carcinogenesis,
Omer Cengiz, and Belma Kocer, and Süleyman Sürmeli, and Mary-Jo Santicky, and Atilla Soran
July 2022, International journal of hematology,
Omer Cengiz, and Belma Kocer, and Süleyman Sürmeli, and Mary-Jo Santicky, and Atilla Soran
June 2015, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Copied contents to your clipboard!